Why Biogen Stock Was a Winner on Wednesday
Prominent biotech (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of quarterly earnings, and investors greeted the estimates-beating numbers by piling into the stock, despite a notable guidance cut. By the end of the trading day, Biogen's shares had gained 6%.
Biogen's total revenue for the first quarter of 2026 was $2.48 billion, up 2% year over year. This was sufficient to top the consensus prognosticator forecast of $2.25 billion.
Image source: Getty Images.
Source Fool.com
Biogen Inc. Stock
€165.76
0.680%
The stock is an absolute favorite of our community with 31 Buy predictions and no Sell predictions.
With a target price of 185 € there is a slightly positive potential of 11.61% for Biogen Inc. compared to the current price of 165.76 €.
